Back to Search Start Over

Primary tumor-derived systemic nANGPTL4 inhibits metastasis.

Authors :
Hübers C
Abdul Pari AA
Grieshober D
Petkov M
Schmidt A
Messmer T
Heyer CM
Schölch S
Kapel SS
Gengenbacher N
Singhal M
Schieb B
Fricke C
Will R
Remans K
Utikal JS
Reissfelder C
Schlesner M
Hodivala-Dilke KM
Kersten S
Goerdt S
Augustin HG
Felcht M
Source :
The Journal of experimental medicine [J Exp Med] 2023 Jan 02; Vol. 220 (1). Date of Electronic Publication: 2022 Oct 21.
Publication Year :
2023

Abstract

Primary tumors and distant site metastases form a bidirectionally communicating system. Yet, the molecular mechanisms of this crosstalk are poorly understood. Here, we identified the proteolytically cleaved fragments of angiopoietin-like 4 (ANGPTL4) as contextually active protumorigenic and antitumorigenic contributors in this communication ecosystem. Preclinical studies in multiple tumor models revealed that the C-terminal fragment (cANGPTL4) promoted tumor growth and metastasis. In contrast, the N-terminal fragment of ANGPTL4 (nANGPTL4) inhibited metastasis and enhanced overall survival in a postsurgical metastasis model by inhibiting WNT signaling and reducing vascularity at the metastatic site. Tracing ANGPTL4 and its fragments in tumor patients detected full-length ANGPTL4 primarily in tumor tissues, whereas nANGPTL4 predominated in systemic circulation and correlated inversely with disease progression. The study highlights the spatial context of the proteolytic cleavage-dependent pro- and antitumorigenic functions of ANGPTL4 and identifies and validates nANGPTL4 as a novel biomarker of tumor progression and antimetastatic therapeutic agent.<br /> (© 2022 Hübers et al.)

Details

Language :
English
ISSN :
1540-9538
Volume :
220
Issue :
1
Database :
MEDLINE
Journal :
The Journal of experimental medicine
Publication Type :
Academic Journal
Accession number :
36269299
Full Text :
https://doi.org/10.1084/jem.20202595